Associations between anticholinergic burden and adverse health outcomes in Parkinson disease

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Crispo, James A G ^a,b   Willis, Allison W ^c   Thibault, Dylan P ^c   Fortin, Yannick ^a   Hays, Harlen D ^d   McNair, Douglas S ^d   Bjerre, Lise M ^a,e,f   Kohen, Dafna E ^a   Perezlloret, Santiago ^g   Mattison, Donald R ^a,h   Krewski, Daniel ^a,h  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CERNER CORPORATION   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f BRUYÈRE RESEARCH INSTITUTE   (Canada)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^h RISK SCIENCES INTERNATIONAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; BACLOFEN; BENZATROPINE MESILATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLOZAPINE; DICYCLOVERINE; DIPHENHYDRAMINE; ENTACAPONE; HALOPERIDOL; LEVODOPA; LOPERAMIDE; LORATADINE; MECLOZINE; METOCLOPRAMIDE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; OXYBUTYNIN; PAROXETINE; PRAMIPEXOLE; PROCHLORPERAZINE MALEATE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SELEGILINE; TOLTERODINE; TRAZODONE; UNINDEXED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ANTICHOLINERGIC BURDEN; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC RISK SCALE; ARTICLE; DELIRIUM; EMERGENCY WARD; FEMALE; FRACTURE; HEALTH CARE UTILIZATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; CHEMICALLY INDUCED; COGNITIVE DEFECT; COHORT ANALYSIS; COMPLICATION; FACTUAL DATABASE; FALLING; FRACTURES, BONE; HOSPITAL EMERGENCY SERVICE; HOSPITAL PATIENT; HOSPITALIZATION; MIDDLE AGED; PREVENTION AND CONTROL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACCIDENTAL FALLS; ADULT; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COHORT STUDIES; DATABASES, FACTUAL; DELIRIUM; EMERGENCY SERVICE, HOSPITAL; FEMALE; FRACTURES, BONE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84961112780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150621     Document Type: Article

References (66)

1. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: A current perspective on use and safety. Expert opinion on drug safety. 2011; 10(5):751-65. Epub 2011/06/04. doi:10.1517/14740338.2011.579899 PMID: 21635190.
2. Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013; 30(10):837-44. Epub 2013/07/25. doi:10.1007/s40266-013-0104-x PMID: 23881698.
3. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001; 62 Suppl 21:11-4. Epub 2001/10/05. PMID: 11584981.
4. Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: A 4-year case-control study. Int Psychogeriatr. 2002; 14(3):307-10. Epub 2002/12/12. PMID: 12475091.
5. Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, et al. Inappropriate medication use and risk of falls-A prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009; 9:30. Epub 2009/07/25. doi:10.1186/1471-2318-9-30 PMID: 19627577; PubMed Central PMCID: PMCPMC2721838.
6. Landi F, Dell'Aquila G, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014; 15(11):825-9. Epub 2014/10/06. doi:10.1016/j.jamda.2014.08.002 PMID: 25282629.
7. Lu WH, Wen YW, Chen LK, Hsiao FY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: A retrospective cohort study. CMAJ. 2015; 187(4): E130-7. Epub 2015/02/04. doi:10.1503/cmaj.141219 PMID: 25646290; PubMed Central PMCID: PMCPMC4347788.
8. Tune LE, Egeli S. Acetylcholine and delirium. Dementia and geriatric cognitive disorders. 1999; 10 (5):342-4. Epub 1999/09/04. 17167. PMID: 10473936.
9. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: A cohort study. Journal of neurology, neurosurgery, and psychiatry. 2010; 81(2):160-5. Epub 2009/09/23. doi:10.1136/jnnp.2009.186239 PMID: 19770163.
10. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. British journal of clinical pharmacology. 2005; 59(2):143-51. Epub 2005/01/29. doi:10.1111/j.1365-2125.2004.02232.xPMID: 15676035; PubMed Central PMCID: PMCPMC1884748.
11. Dispennette R, Elliott D, Nguyen L, Richmond R. Drug Burden Index score and anticholinergic risk scale as predictors of readmission to the hospital. The Consultant pharmacist: The journal of the American Society of Consultant Pharmacists. 2014; 29(3):158-68. Epub 2014/03/05. doi:10.4140/TCP.n.2014.158 PMID: 24589765.
12. Fraser LA, Adachi JD, Leslie WD, Goltzman D, Josse R, Prior J, et al. Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period. The Annals of pharmacotherapy. 2014; 48(8):954-61. Epub 2014/05/13. doi:10.1177/1060028014535363 PMID: 24816210.
13. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015; 63(1):85-90. Epub 2015/01/20. doi:10.1111/jgs.13206 PMID: 25597560.
14. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. European journal of clinical pharmacology. 2013; 69(7):1485-96. Epub 2013/03/27. doi:10.1007/s00228-013-1499-3 PMID: 23529548.
15. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr. 2015; 15:31. Epub 2015/04/17. doi:10.1186/s12877-015-0029-9 PMID: 25879993; PubMed Central PMCID: PMCPMC4377853.
16. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011; 221 (2):564-73. Epub 2010/01/12. doi:10.1016/j.bbr.2009.12.048 PMID: 20060022; PubMed Central PMCID: PMCPMC2888997.
17. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2011; 26(14):2496- 503. Epub 2011/09/08. doi:10.1002/mds.23932PMID: 21898597.
18. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of internal medicine. 2008; 168(5):508-13. Epub 2008/03/12. doi:10.1001/archinternmed.2007.106 PMID: 18332297.
19. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. Epub 2005/10/15. PMID: 16224307.
20. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47 (6):626-33. Epub 2009/05/13. doi:10.1097/MLR.0b013e31819432e5 PMID: 19433995.
21. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157 (11):1015-22. Epub 2003/06/05. PMID: 12777365.
22. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: A population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010; 34 (3):143-51. Epub 2010/01/22. doi:10.1159/000275491 PMID: 20090375; PubMed Central PMCID: PMCPmc2865395.
23. Paul KJ, Walker RL, Dublin S. Anticholinergic medications and risk of community-Acquired pneumonia in elderly adults: A population-based case-control study. J Am Geriatr Soc. 2015; 63(3):476-85. Epub 2015/03/03. doi:10.1111/jgs.13327 PMID: 25726764.
24. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008; 56(7):1333-41. Epub 2008/05/31. doi:10.1111/j.1532-5415.2008.01737.x PMID: 18510583.
25. Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, et al. Anticholinergic burden in Parkinson's disease inpatients. European journal of clinical pharmacology. 2015; 71(10):1271-7. Epub 2015/08/10. doi:10.1007/s00228-015-1919-7 PMID: 26254777.
26. Bhattacharya RK, Dubinsky RM, Lai SM, Dubinsky H. Is there an increased risk of hip fracture in Parkinson's disease? A nationwide inpatient sample. Movement disorders: official journal of the Movement Disorder Society. 2012; 27(11):1440-3. Epub 2012/06/30. doi:10.1002/mds.25073 PMID: 22744727.
27. Harris-Hayes M, Willis AW, Klein SE, Czuppon S, Crowner B, Racette BA. Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures. J Bone Joint Surg Am. 2014; 96(4):e27. Epub 2014/02/21. doi:10.2106/jbjs.l.01317 PMID: 24553896; PubMed Central PMCID: PMCPMC3918936.
28. Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson's disease: A large Australian retrospective study. Journal of neurology, neurosurgery, and psychiatry. 2015; 86(3):324- 30. Epub 2014/05/31. doi:10.1136/jnnp-2014-307822 PMID: 24876185.
29. Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015; 85(5):413-9. Epub 2015/07/04. doi:10.1212/wnl.0000000000001715 PMID: 26138947; PubMed Central PMCID: PMCPMC4534080.
30. Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Predictors of survival in patients with Parkinson disease. Archives of neurology. 2012; 69(5):601-7. Epub 2012/01/04. doi:10.1001/archneurol.2011.2370 PMID: 22213411; PubMed Central PMCID: PMCPMC3599783.
31. Khan BA, Zawahiri M, Campbell NL, Fox GC, Weinstein EJ, Nazir A, et al. Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research-A systematic evidence review. J Hosp Med. 2012; 7(7):580-9. Epub 2012/06/12. doi:10.1002/jhm.1949 PMID: 22684893; PubMed Central PMCID: PMCPMC3640527.
32. Naja M, Zmudka J, Hannat S, Liabeuf S, Serot JM, Jouanny P. In geriatric patients, delirium symptoms are related to the anticholinergic burden. Geriatr Gerontol Int. 2015. Epub 2015/05/09. doi:10.1111/ggi.12485 PMID: 25952295.
33. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013; 30(2):103-12. Epub 2012/12/15. doi:10.1007/s40266-012-0044-x PMID: 23239364.
34. Kolanowski A, Mogle J, Fick DM, Campbell N, Hill N, Mulhall P, et al. Anticholinergic Exposure During Rehabilitation: Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia. Am J Geriatr Psychiatry. 2015. Epub 2015/10/01. doi:10.1016/j.jagp.2015.07.004 PMID: 26419732.
35. Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: A nested case-control study. PloS one. 2014; 9(6):e94944. Epub 2014/06/03. doi:10.1371/journal.pone.0094944 PMID: 24887491; PubMed Central PMCID: PMCPMC4041721.
36. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement disorders: officialjournal of the Movement Disorder Society. 2015; 30(7):919-27. Epub 2015/03/05. doi:10.1002/mds.26170 PMID: 25737166.
37. Yarnall AJ, Lawson RA, Duncan GW, Breen DP, Khoo TK, Brooks D, et al. Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease? Journal of Parkinson's disease. 2015; 5(4):743- 7. Epub 2015/10/08. doi:10.3233/jpd-150664 PMID: 26444094.
38. Bedard MA, Lemay S, Gagnon JF, Masson H, Paquet F. Induction of a transient dysexecutive syndrome in Parkinson's disease using a~subclinical dose of scopolamine. Behavioural neurology. 1998; 11(4):187-95. Epub 2001/09/25. PMID: 11568419.
39. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Archives of internal medicine. 2009; 169(14):1317-24. Epub 2009/07/29. doi:10.1001/archinternmed.2009.229 PMID: 19636034; PubMed Central PMCID: PMCPmc2933398.
40. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Intern Med. 2015; 175(3):401-7. Epub 2015/01/27. doi:10.1001/jamainternmed.2014.7663PMID: 25621434; PubMed Central PMCID: PMCPmc4358759.
41. Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB, et al. Drug burden index score and functional decline in older people. Am J Med. 2009; 122(12):1142-9.e1-2. Epub 2009/12/05. doi:10.1016/j.amjmed.2009.02.021 PMID: 19958893; PubMed Central PMCID: PMCPmc3263511.
42. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Archives of internal medicine. 1991; 151(9):1825-32. Epub 1991/09/01. PMID: 1888249.
43. Skoldunger A, Fastbom J, Wimo A, Fratiglioni L, Johnell K. Impact of Inappropriate Drug Use on Hospitalizations, Mortality, and Costs in Older Persons and Persons with Dementia: Findings from the SNAC Study. Drugs Aging. 2015. Epub 2015/08/02. doi:10.1007/s40266-015-0287-4 PMID: 26232101.
44. Lund BC, Schroeder MC, Middendorff G, Brooks JM. Effect of hospitalization on inappropriate prescribing in elderly Medicare beneficiaries. J Am Geriatr Soc. 2015; 63(4):699-707. Epub 2015/04/10. doi:10.1111/jgs.13318 PMID: 25855518.
45. Mattison ML, Afonso KA, Ngo LH, Mukamal KJ. Preventing potentially inappropriate medication use in hospitalized older patients with a computerized provider order entry warning system. Archives of internal medicine. 2010; 170(15):1331-6. Epub 2010/08/11. doi:10.1001/archinternmed.2010.244 PMID: 20696957; PubMed Central PMCID: PMCPMC3638236.
46. Morris M, Willis AW, Searles Nielsen S, McCann F, Birke A, Racette BA. Physician response to a medication alert system in inpatients with levodopa-Treated diseases. Neurology. 2015; 85(5):420-4. Epub 2015/06/21. doi:10.1212/wnl.0000000000001745 PMID: 26092916; PubMed Central PMCID: PMCPMC4534077.
47. Thompson NR, Fan Y, Dalton JE, Jehi L, Rosenbaum BP, Vadera S, et al. A new Elixhauser-based comorbidity summary measure to predict in-hospital mortality. Med Care. 2015; 53(4):374-9. Epub 2015/03/15. doi:10.1097/mlr.0000000000000326 PMID: 25769057.
48. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiology and drug safety. 2006; 15(5):291-303. Epub 2006/02/01. doi:10.1002/pds.1200 PMID: 16447304.
49. Boorsma M, Joling KJ, Frijters DH, Ribbe ME, Nijpels G, van Hout HP. The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry. 2012; 27(7):709-15. Epub 2011/09/16. doi:10.1002/gps.2770 PMID: 21919058.
50. Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA. Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes. Movement disorders: official journal of the Movement Disorder Society. 2005; 20(4):410-5. Epub 2004/12/08. doi:10.1002/mds.20347 PMID: 15580552.
51. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics: The official journal of the Japanese Psychogeriatric Society. 2013; 13(1):17-24. Epub 2013/04/05. doi:10.1111/j.1479-8301.2012.00418.x PMID: 23551407.
52. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, Medrano J. Confusion regarding anticholinergic burden measurement. J Am Geriatr Soc. 2015; 63(5):1054. Epub 2015/05/20. doi:10.1111/jgs.13411 PMID: 25989588.
53. Mayer T, Haefeli WE, Seidling HM. Different methods, different results-how do available methods link a patient's anticholinergic load with adverse outcomes? European journal of clinical pharmacology. 2015; 71(11):1299-314. Epub 2015/09/10. doi:10.1007/s00228-015-1932-xPMID: 26350641.
54. Naples JG, Marcum ZA, Perera S, Gray SL, Newman AB, Simonsick EM, et al. Concordance Between Anticholinergic Burden Scales. J Am Geriatr Soc. 2015; 63(10):2120-4. Epub 2015/10/21. doi:10.1111/jgs.13647 PMID: 26480974; PubMed Central PMCID: PMCPmc4617193.
55. Pont LG, Nielen JT, McLachlan AJ, Gnjidic D, Chan L, Cumming RG, et al. Measuring anticholinergic drug exposure in older community-dwelling Australian men: A comparison of four different measures. British journal of clinical pharmacology. 2015; 80(5):1169-75. Epub 2015/04/30. doi:10.1111/bcp.12670 PMID: 25923961; PubMed Central PMCID: PMCPmc4631189.
56. Lertxundi U, Domingo-Echaburu S, Ruiz-Osante B, Hernandez Palacios R, Peral Aguirregoitia J, Medrano Albeniz J. Comments on Duran et al.'s systematic review of anticholinergic risk scales (EJCP 2DOI 10.1007/s00228-013-1499-3). European journal of clinical pharmacology. 2013; 69(9):1729. Epub 2013/06/07. doi:10.1007/s00228-013-1535-3 PMID: 23740000.
57. Villalba-Moreno AM, Alfaro-Lara ER, Perez-Guerrero MC, Nieto-Martin MD, Santos-Ramos B. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr. 2016; 62:1-8. Epub 2015/11/01. doi:10.1016/j.archger.2015.10.002 PMID: 26518612.
58. Koshoedo S, Soiza RL, Purkayastha R, Mangoni AA. Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation. The American journal of geriatric pharmacotherapy. 2012; 10(4):251-7. Epub 2012/07/17. doi:10.1016/j.amjopharm.2012.06.003 PMID: 22795433.
59. Lowry E, Woodman RJ, Soiza RL, Mangoni AA. Clinical and demographic factors associated with antimuscarinic medication use in older hospitalized patients. Hospital practice (1995). 2011; 39(1):30-6. Epub 2011/03/29. doi:10.3810/hp.2011.02.371 PMID: 21441756.
60. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martinez-Bengoechea MJ, Garcia-Monco JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists. 2008; 65(5):414-9. Epub 2008/02/19. doi:10.2146/ajhp060624 PMID: 18281732.
61. Martinez-Ramirez D, Giugni JC, Little CS, Chapman JP, Ahmed B, Monari E, et al. Missing dosages and neuroleptic usage may prolong length of stay in hospitalized Parkinson's disease patients. PloS one. 2015; 10(4):e0124356. Epub 2015/04/18. doi:10.1371/journal.pone.0124356 PMID: 25884484; PubMed Central PMCID: PMCPmc4401689.
62. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ (Clinical research ed). 2012; 344:e977. Epub 2012/03/01. doi:10.1136/bmj.e977 PMID: 22362541; PubMed Central PMCID: PMCPmc3285717.
63. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012; 169(1):71-9. Epub 2011/12/24. doi:10.1176/appi.ajp.2011.11030347 PMID: 22193526; PubMed Central PMCID: PMCPmc4269551.
64. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015; 72(5):438-45. Epub 2015/03/19. doi:10.1001/jamapsychiatry.2014.3018 PMID: 25786075; PubMed Central PMCID: PMCPmc4439579.
65. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66(7):996-1002. Epub 2006/04/12. doi:10.1212/01.wnl.0000215428.46057.3d PMID: 16606910.
66. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2011; 26 Suppl 3:S42-S80. Epub 2011/11/02. doi:10.1002/mds.23884 PMID: 22021174; PubMed Central PMCID: PMCPmc4020145.